A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

Thank you to Madrigal for sponsoring this Journal Club Video Module!

In this GHAPP Journal Club review, Lisa Richards, a board-certified family nurse practitioner specializing in hepatology at UC San Diego Health, presents pivotal research from a February 2024 New England Journal of Medicine publication. The phase 3 randomized controlled trial evaluated the efficacy of Resmineron, the first FDA-approved therapy for non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis. Lisa discusses key findings from the study, including improvements in liver fibrosis and NASH resolution in patients treated with Resmineron compared to placebo. Join her for an in-depth look at this groundbreaking therapy and its impact on patient care.